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Letters to the EditorPanimmunoglobulin and IgE-selec-
tive extracorporeal immunoadsorp-
tion in patients with severe atopic
dermatitisTo the Editor:
Atopic dermatitis (AD) is a pruritic, usually eczematous
inflammatory skin disease that involves skin barrier dysfunction
in concert with immunologic abnormalities driven by dendritic
cells, T cells, and eosinophils and characterized by the presence of
distinct cytokine and chemokine circuits.1 There is a high unmet
therapeutic need, especially for patients with persistent severe
disease.2 A currently discussed new treatment strategy aims at
reducing circulating IgE levels, which are often increased in pa-
tients with severe chronic AD and correlate with disease severity.3
The anti-IgE antibody omalizumab has been tried,4 but results in
patients with AD have not been definitive.
In a small pilot study using extracorporeal immunoadsorp-
tion with columns that bind all immunoglobulin classes
(panimmunoglobulin [pan-Ig] immunoadsorption), parameters
of cutaneous inflammation normalized parallel to a clinical
improvement in AD.5 Here we compared the clinical effects
of pan-Ig immunoadsorption with those of IgE-selective im-
munoadsorption using newly developed columns selective
for human IgE in 50 adult patients (>18 years old) with severe
recalcitrant AD. Immunoadsorption is an approved therapeu-
tic procedure in Germany, and treatment costs for these re-
fractory cases were covered by public and private health
insurers. Data collection and analysis were done as part of
an immunoadsorption registry in the setting of an open-label
comparative trial.
Extracorporeal pan-Ig (n 5 24) and IgE-selective immuno-
adsorption (n5 26) weremanaged by an interdisciplinary team of
dermatologists, nephrologists, and specially trained nurses. Each
patient received a total of 10 immunoadsorption sessions over a
2-month period divided into 3 cycles of 4 consecutive days in
week 1, 3 days in week 4, and 3 days in week 8. Patients were
hospitalized for each immunoadsorption cycle and assessed
before immunoadsorption (visit 1), between the second and third
cycles (visit 2), and at approximately 1 month (visit 3) and
6 months (visit 4) after immunoadsorption (Fig 1). Details of
patients’ characteristics (see Table E1 in this article’s Online
Repository at www.jacionline.org) and management, severity
definitions, registry settings, and immunoadsorption procedures
are presented in the Methods section in this article’s Online
Repository at www.jacionline.org.
The mean Eczema Area and Severity Index (EASI) was 21.3,
and the majority of patients had excessive IgE levels of between
5,000 and 10,000 kU/L before therapy. Both immunoadsorption
types reduced peripheral IgE levels by approximately 85% to 90%
per immunoadsorption cycle, but only pan-Ig immunoadsorption
also had significant effects on circulating IgG levels (see Fig E1
and further details in the Results section in this article’s Online
Repository at www.jacionline.org). 2016 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1882The main effects, as measured by reductions in EASI and
Dermatology Life Quality Index (DLQI), occurred between visits
1 and 2 and remained stable up to visit 4 (Fig 2, upper panels). The
median EASI reductions in the IgE-selective immunoadsorption
group were 47% (95% CI, 31% to 59%) at visit 2, 45% (95%
CI, 20% to 57%) at visit 3, and 60% (95%CI, 17% to 66%) at visit
4 (all P < .005), which is similar to reductions seen in the pan-Ig
immunoadsorption group (visit 2: 39% [95% CI, 11% to 58%],
visit 3: 52% [95% CI, 30% to 66%], and visit 4: 61% [95% CI,
29% to 71%]; all P < .005). Almost 50% of the patients treated
with either immunoadsorption procedure achieved an EASI50
response (ie, an at least 50% reduction of the baseline EASI) by
visit 2, and approximately 30% achieved a DLQI of 5 or less
(mild effect of the disease). As shown in the lower panels of
Fig 2, these percentages remained stable until visit 4 in the
IgE-selective immunoadsorption group and slightly increased in
the pan-Ig immunoadsorption group. Improvements in EASI
and DLQI were paralleled by reductions in the clinical signs
domain of the SCORAD index (objective SCORAD) and the
Patient-Oriented Eczema Measure (POEM, see Fig E2 in this
article’s Online Repository at www.jacionline.org). At visit 3,
pruritus and sleep scales indicated mean improvements among
EASI50 responders of 54% and 55%, respectively. Of the 12
patients with systemic therapy at visit 1, treatment could be
stopped in 6 by visit 3 and reduced in another 2 (see also
Table E1). Logistic regression analysis revealed 3 dichotomous
baseline variables to influence EASI50 response by visit 3. If
systemic therapy was present at baseline, the IgE less was less
than 6700 kU/L (sample median), and the EASI was 17 or greater
(sample median), the probability of achieving an EASI50
response was 75% compared with 15% in the absence of any of
these factors (see Fig E3 in this article’s Online Repository at
www.jacionline.org).
While there were no major differences in clinical effects
between the 2 immunoadsorption treatment groups, 2 adverse
events (AEs) were recorded in the IgE-selective immunoadsorp-
tion group, neither of which are considered related to
immunoadsorption, compared with 8 AEs in 7 patients in the
pan-Ig immunoadsorption group, all of which were considered
related to immunoadsorption. The latter included 2 mild cases of
herpes labialis and 3 severe infectious AEs that required systemic
therapy: 1 case each of herpes keratitis caused by HSV-1,
bacterial conjunctivitis caused by Staphylococcus aureus, and
bacterial sinusitis.
The results of our findings suggest that IgE-selective immu-
noadsorption is a potential treatment option in patients with
severe AD that deserves further investigation. The available data
for another new promising treatment for AD, the IL-4 receptor a
chain antagonist dupilumab, indicate that EASI50 responses
might be achievable in more than 80% of patients after 16 weeks
of weekly injections,6 but the results are difficult to compare with
those reported here because of differences in the treated patient
populations.
The exact mechanisms underlying the clinical response in
patients with AD to immunoadsorption are incompletely under-
stood. Importantly, comparisons of skin-bound and peripheral IgE
levels in the earlier pilot trial5 indicated that reductions in the
latter are transient but associated with and probably responsible
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FIG 2. Clinical effects of immunoadsorption. EASI and DLQI over time (medians and 95% CIs; upper panels)
and percentages of EASI responders (EASI50) and DLQI responders (DLQI <_ 5) over time (medians and 95%
CIs; lower panels) are shown. For time points of visits 1 to 4, see Fig 1.
FIG 1. Schematic illustration of the immunoadsorption (IA) procedure. Shown are the 3 immunoadsorption
cycles (IA 1 to IA 3; the given days represent the duration of each cycle) and visits 1 to 4, which were used for
collection of clinical data (median days and range relative to immunoadsorption cycles).
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LETTERS TO THE EDITOR 1883for more sustainable reductions in the former. Because decreases
in skin-bound IgE levels correlated with immunologic and
clinical improvements, we speculate that this indirect effect
contributes to AD improvement caused by immunoadsorption.
At the time the pan-Ig proof-of-concept study was performed,
IgE-selective immunoadsorption columns were not yet available.
Pan-Ig immunoadsorption is potentially associated with removal
of protective immunoglobulin, a drawback in patients with severe
AD, who have an increased susceptibility to skin infections by
pathogens such as S aureus and Herpes simplex. The results of
the present study in conjunction with earlier case reports7,8
indicate that IgE-selective immunoadsorption is indeed as
effective as pan-Ig immunoadsorption but probably safer with
regard to infectious events.We thank all patients participating in this observational study and
acknowledge the expert assistance of the nurses at the Nephrology Centre
Reinbek and Geesthacht, namely Luis Viana, Evelyn Pechler, Silke de Jong,
Nadine Alt, and Petra Dahlhaus. We also thank Miltenyi Biotec GmbH for
their support in this study.
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birch pollen allergyTo the Editor:
IgE plays a critical role during allergic inflammation by
sensitizing mast cells and basophils. The number of IgE-
expressing B cells and plasma cells is generally very low, and it
is therefore difficult to directly study their development and
homeostasis.1 The diversity and persistence of the human IgE
repertoire is largely unknown (reviewed in Gadermaier et al2).
IgE switching can occur directly (IgM5>IgE) or indirectly
(IgM5>IgG15>IgE in mice
3 and IgM5>IgG1/IgG2/IgG3/
IgG45>IgE in humans
4). Studies in mice revealed that indirect
IgE switching is required for the generation of high-affinity IgE
responses.5 However, current data provide only little evidence
that IgE responses in allergic individuals are also dependent on
sequential switching (reviewed in Davies et al6). Direct compar-
isons between the repertoires of IgE and other immunoglobulin
isotypes from individual subjects have not been reported. Further-
more, only little information is currently available regarding
changes in the IgE repertoire of individual subjects over time.7Here, we used next-generation sequencing (NGS) to analyze
thousands of immunoglobulin heavy chain VDJ (variable,
diversity, joining regions) sequences of different isotypes from
the peripheral blood of 3 patients diagnosed with allergy to birch
pollen. A similar approach was recently used to reveal
overlapping IgE repertoires between nasal biopsies and blood
samples of patients with allergic rhinitis.8 The 3 female patients
were of similar age (50-59 years old) and characterized by high
serum IgE CAP fluorescent enzyme immunoassay (FEIA) (class
4-6) to birch pollen extract or CAP FEIA class 5 or higher for the
major birch pollen allergen Bet v 1. In addition, patients 1 and 2
showed a low anti–Bet v 2 IgE level while patient 3 was sensitized
to Bet v 4, although the Immunoblot showed only a weak band
at 8 kDa (see Fig E1 in this articles’s Online Repository at
www.jacionline.org). Patients 1 and 3 also responded to many
other allergens by skin prick test, and they had been treated
with sublingual immunotherapy more than 10 years ago without
long-term success (see Fig E2 and Tables E1 and E2 in this
article’s Online Repository at www.jacionline.org). To determine
the complexity of the IgE repertoire in comparison to other
immunoglobulin isotypes in these patients, we isolated RNA
from PBMCs and generated RT-PCR products with 59 primers
specific for the leader region in immunoglobulin VH1, VH3,
and VH4 genes, which cover the vast majority of the expressed
human VH genes, and a set of 39 primers binding in the first
exon of the constant region of different CH genes as described
in this article’s Methods section in the Online Repository at
www.jacionline.org. The RT-PCR products were analyzed by
NGS and afterwards filtered for the individual isotypes IgM,
IgA1, IgA2, IgG1, IgG2, and IgE. IgG3 and IgG4 sequences were
not included in the analysis because we obtained only less than
100 sequences from these isotypes.
Several thousand sequences were obtained from each
immunoglobulin isotype, and 70% to 80% of these sequences
were productive (see Fig E3, A and B, in this article’s Online
Repository at www.jacionline.org). The complementarity
determining region of the immunoglobulin heavy chain
(CDRH) 3 is a short DNA sequence that covers the VDJ junction
of the immunoglobulin heavy chain, is extremely diverse, and can
be used as an identifier for individual clones of B cells or plasma
cells. The IgM, IgA, and IgG repertoires were composed of 150 to
300 individual CDRH3 regions among 1000 randomly selected
sequences, whereas the IgE repertoires were less complex with
only 50 to 100 different CDRH3 regions in 1000 sequences
(Fig E3, C). All 3 parameters were comparable between birch
pollen season 2013 (S_2013) and season 2013 (S_2014).
To determine whether IgE sequences use the same V, D, and
J gene families as other immunoglobulin isotypes, we compared
the average usage of different families of these segments. The
usage of VH3 and DH3 dominated in all isotypes except IgE in
which VH4 genes and DH5 elements were most often used (see
Fig E4 in this article’s Online Repository at www.jacionline.org).
This observation was made with sequences from S_2013 and
S_2014 arguing for a persistent difference between VH and DH
usage of IgE versus all other isotypes.
Studies in the mouse have indicated that the IgE repertoire can
overlap with the IgG1 repertoire,
3 but it remains unclear whether
sequential IgE switching via IgG makes a significant contribution
to the total IgE repertoire in humans. We compared the CDRH3
region of 1000 randomly picked IgE sequences with 1000
sequences of other isotypes by using theMorisita-Horn algorithm
METHODS
Patients and assessments
All patients were originally seen in a special outpatient clinic for patients
with difficult AD at the Dermatologikum Hamburg. The collected data
included a detailed medical history; assessments of disease severity, such as
EASI and scores on the clinical signs domain of the SCORAD index
(objective SCORAD); and assessments of health-related quality of life
(HR-QoL), including DLQI and POEM score, according to current
recommendations for the management of severe AD.E1,E2 Pruritus and sleep
were assessed by using a 0- to 10-point numeric rating scale.E3 Adults
(>18 years) with severe recalcitrant active AD of the extrinsic type (IgE
>150 kU/L)E4 were offered treatment with either pan-Ig or IgE-selective
immunoadsorption.
In the absence of a broadly accepted definition of severe AD and a low
correlation between absolute EASI andDLQI (data not shown), we considered
patients who, despite expert management, either had an EASI of greater than
10 and/or a DLQI of greater than 10 (severe effect on HR-QoL)E5 to be in
alignment with the disease severity classification used for psoriasis.E6 We
found that the majority of patients fulfilling these criteria were (1) either pa-
tients with high EASI who did not respond to or had significant side effects
or contraindications to treatment with systemic corticosteroids and cyclo-
sporine or (2) patients with a DLQI of greater than 10 despite ongoing immu-
nosuppressive therapy, such as cyclosporine, methotrexate, azathioprine, or
mycophenolate mofetil.
All clinical assessments were performed by a team initially blinded to the
type of immunoadsorption. Topical and/or systemic treatments were
continued andmodified as needed. Patients were informed about the treatment
procedure and the collection of data and providedwritten informed consent for
both. The patients described in this article were treated between April 2012
and March 2015.
Immunoadsorption
Immunoadsorption was managed by an interdisciplinary team of
dermatologists, nephrologists, and nurses who were specially trained for
pan-Ig and IgE-selective immunoadsorption. A nephrologist carefully
examined all patients to confirm eligibility for immunoadsorption and
performed venous ultrasonography of both arms to determine venous access.
Each patient received a total of 10 immunoadsorption sessions over a 2-month
period divided into 3 cycles of 4 consecutive days in week 1, 3 days in week 4,
and 3 days in week 8. Patients were hospitalized for each immunoadsorption
cycle at the St. Adolf-Stift and closely monitored by the interdisciplinary
immunoadsorption team. Patients received 2 g of cefazolin or, in the case of a
history of cephalosporin intolerance, 1 g of fosfomycin as a prophylactic
intravenous bolus on the first day of each cycle.
Immunoadsorption was performed with reusable adsorption columns
containing a matrix coated with either mouse anti-human IgE (TheraSorb
IgE; Miltenyi Biotec, Teterow, Germany) or polyclonal sheep anti-human
immunoglobulin antibodies (TheraSorb Ig-Flex, Miltenyi Biotec) and the
LIFE 18Apheresis Unit (Miltenyi Biotec). Two adsorption columnswere used
per patient, allowing for adsorber regeneration during immunoadsorption. The
adsorbers have a binding capacity of approximately 0.6 g of total immuno-
globulin and 5 million IU of IgE per plasma loading cycle, respectively, but
total binding capacity per treatment is not limited because of repeated plasma
loading and regeneration of the adsorbers. During each immunoadsorption
session, at least the 2-fold plasma volume was processed, as calculated
according to Sprenger et al.E7 When possible, the median cubital or cephalic
veins of both arms were used for venous access, generating a blood flow of at
least 70 mL/min. Of the 500 immunoadsorption sessions reported here, 55
(11%) sessions in 8 patients required a central venous catheter. Anticoagula-
tion was achieved by a bolus injection of 5000 IU of sodium heparin and
anticoagulant citrate dextrose, formula A (ACD-A; Baxter, Munich,
Germany). The ratio of ACD-A to whole blood was adjusted to maintain a
free calcium concentration in the extracorporeal circuit of less than
0.3 mmol/L, as determined by means of bedside testing every 30 minutes
(GEM Premier 3000; Instrumentation Laboratories, Zaventem, Belgium).
Intravenous calcium was substituted if the patient’s free serum calcium con-
centration decreased to less than 0.9 mmol/L.
The immunoadsorption session was terminated if the treatment time
exceeded 4.5 hours or once the 2.8-fold plasma volume had been processed.
To compare and confirm the specificity of the 2 different immunoadsorption
procedures, IgE and IgG levels were determined immediately before and after
each apheresis cycle. In addition, to determine the removal of proteins and
immunoglobulins in each immunoadsorption session, the total eluate of the
rinsed columns was collected in 5 patients of each treatment group over 1
cycle by using 10-L containers. A 10-mL sample of the mixed eluate was sent
for laboratory diagnostic analysis, with all parameters analyzed within 12 to
24 hours (Aesculabor, Hamburg, Germany).
Statistical analyses
Patients’ characteristics, IgE levels, and clinical scores were described by
summary statistics (sample size, mean6 SD, and/or median and related 95%
CI, where applicable). Box-and-whisker plots (with median, interquartile
range box, and 10% and 90% whiskers) were applied to inspect the
distributions of quantitative target variables. EASI and DLQI over time
were intraindividually evaluated by using median values and related CIs. For
comparison of both treatment groups, the Hodges-Lehmann point estimator
and CI were chosen to estimate group differences.E8,E9 EASI and DLQI
observed at visits 2 to 4 were intraindividually compared with baseline values
by using the Wilcoxon signed-rank test, with P values of less than .05 set to
indicate significance.
Patients presenting at the follow-up visits with an individual 50% decrease
in EASI comparedwith baseline or patients with DLQI of 5 points or less were
considered responders and are listed with frequencies, percentages, and
related CIs, if applicable. The EASI response distribution was investigated by
using logistic regression to identify important prognostic factors that would
explain differences in treatment response.E10 Awide range of possible factors
was included, such as sex, age, baseline clinical scores, IgE levels, and use of
systemic medication.
Finally, response probabilities were estimated for the set of events caused by
these specific factors. Calculations were done with SAS statistical software
(version 9.1.2 [2013]; SAS Institute, Cary, NC). Data evaluation was performed
as an explorative analysis, applying robust estimators without the need for
normal distributeddata. Strategies to prevent bias causedbymissing valueswere
not considered because of the small number of missing values.
RESULTS
Baseline patients’ characteristics
The characteristics of the treated patients are presented in
Table E1. The majority of patients had long-standing severe AD
with largely impaired HR-QoL. Because of the heterogeneity of
eligible patients, including patients with severe AD (EASI >10)
with no systemic therapy possible and patients with significant
disease (DLQI >10) despite ongoing systemic therapy (see the
Methods section), there was some variation in clinical activity
scores. Forty (80%) patients either had an EASI of greater than
20 or a DLQI of greater than 10, and 22 patients (44%) had
both. More than 40% (22/50) of patients received systemic
therapies in the last 3 months and more than 80% (42/50) of
patients received systemic therapies in the last 12 months before
immunoadsorption, with the majority of them being systemic
corticosteroids or cyclosporine. Twelve (24%) patients had
ongoing systemic therapy at baseline (visit 1), and 2 of these
patients had more than 1 systemic therapy (Table E1). There
were no major baseline differences between patients receiving
pan-Ig and those receiving IgE-selective immunoadsorption,
except that the latter tended to have lower clinical activity scores,
possibly explained by a higher number of baseline patients with
concurrent cyclosporine.
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Effects of different immunoadsorption procedures
on circulating IgE and IgG levels
Circulating IgE and IgG levels before and after each
immunoadsorption cycle are shown in Fig E1. Peripheral
immunoglobulin levels before immunoadsorption cycle 1 corre-
spond to baseline levels before treatment. Themajority of patients
had excessive pretreatment IgE levels of between 5,000 and
10,000 kU/L, with comparable distributions of values in both
immunoadsorption treatment groups. IgE-selective immuno-
adsorption decreased median peripheral IgE levels by
approximately 90% with each treatment cycle and peripheral
IgG levels by approximately 20%.
Pan-Ig immunoadsorption reduced median peripheral IgE
levels and also peripheral IgG levels by approximately 85%
with each cycle. Effects of both immunoadsorption procedures on
peripheral IgE and IgG levels were transient because precycle
values remained similar over time.
Based on the analysis of 1 immunoadsorption cycle for 5
patients in each immunoadsorption treatment group, more than
4 mg of IgE was removed on average per immunoadsorption
session (1 day) with both immunoadsorption procedures
compared with approximately 12.5 g of IgG with the pan-Ig
immunoadsorption and 1.4 g of IgG with the IgE-selective
immunoadsorption procedures, respectively (data not shown).
Reduction of IgG plasma concentrations with IgE-selective
immunoadsorption is explained by 2 effects: the dilution of
plasma during treatment with the infused ACD-A solution and the
small loss of plasma (on average, between 10 and 15 mL per
adsorption cycle) that occurs during the switch between the 2
adsorber columns.
Comparability of different clinical and HR-QoL
parameters
Fig E2 shows that EASI andDLQI reductions at visit 3, approx-
imately 1 month after the final immunoadsorption cycle, were
paralleled by reductions in objective SCORAD and POEM
scores, although the effects appeared to be less pronounced.
Logistic regression analysis of response
Logistic regression analysis revealed 3 dichotomous baseline
variables that influenced the EASI50 response to immunoadsorption
by visit 3, namely systemic therapy (if present at baseline), an IgE
baseline value of less than 6700 kU/L (corresponding to the sample
median), and a baseline EASI of 17 or greater (corresponding to the
sample median). As shown in Fig E3, the probability to achieve an
EASI50 response was 15% in the absence of any of these factors
but 75% in the presence of all 3 factors.
Details of safety findings
The 8 AEs occurring in 7 patients in the pan-Ig immuno-
adsorption group included 2mild cases of herpes labialis, 3 severe
infectious AEs (1 case each of herpes keratitis caused by HSV-1,
bacterial conjunctivitis caused by S aureus, and bacterial
sinusitis, all requiring systemic therapy), and 3 serious AEs
(1 case each of air embolism during central venous catheter
placement, cubital vein thrombophlebitis, and generalized
cutaneous allergic reaction to prophylactic antibiotic therapy,
all requiring hospitalization). All AEs completely resolved during
follow-up.
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FIG E1. Effect of immunoadsorption (IA) on peripheral immunoglobulin levels. Box plots and means of
peripheral IgE (upper panels) and IgG (lower panels) levels before and after each immunoadsorption cycle
in patients receiving IgE-selective immunoadsorption (left panels) and pan-Ig immunoadsorption (right
panels) are shown.
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FIG E2. Comparison of clinical and HR-QoL scores used during immunoadsorption. Box plots andmeans of
relative reductions of clinical scores (EASI and objective SCORAD scores) and HR-QoL parameters (DLQI
and POEM scores) at visit 3 compared with baseline (visit 1) are shown.
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FIG E3. Parameters influencing response to immunoadsorption. The
illustration shows the estimated probability of the EASI50 response after
immunoadsorption treatment related to the presence of 0, 1, 2, or 3 of the
following baseline parameters determined by means of logistic regression
analysis: (1) EASI of 17 or greater; (2) consumption of at least 1 systemic
medication; and (3) peripheral IgE level of less than 6700 kU/L. The highest
EASI50 response probability of 75% was calculated for patients with all 3
parameters at baseline.
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TABLE E1. Patients’ characteristics
All
therapies Pan-Ig
IgE
selective
No. 50 24 26
Sex (M/F) 30/20 14/10 16/10
Age (y), mean 6 SD 45.6 6 11.0 44.3 6 12.5 46.8 6 9.5
Age (y), median (range) 46.5 (21-75) 46 (21-63) 47 (24-75)
Duration of AD (y),
mean 6 SD
36.9 6 13.3 35.0 6 14.0 38.5 6 12.7
SCORAD score
(mean 6 SD)
40.5 6 14.2 46.3 6 13.6 35.1 6 12.7
EASI (mean 6 SD) 21.3 6 15.5 24.1 6 15.2 18.7 6 15.6
DLQI (mean 6 SD) 15.3 6 6.9 15.9 6 7.3 14.8 6 6.6
POEM score
(mean 6 SD)
20.4 6 5.9 20.9 6 5.3 19.9 6 6.4
Visit 1/2/3/4 (no.) 50/49/49/47 24/24/24/22 26/25/25/25
Concurrent therapies (visit 1/2/3/4)
Topical
None 5/7/7/4 2/3/2/2 3/4/3/2
TCS 30/32/30/28 16/17/16/14 14/15/14/14
TCI 1/0/1/2 0/0/1/1 1/0/0/1
TCS1TCI 14/10/13/13 6/4/5/5 8/6/8/8
Systemic therapies
None 38/41/41/39 19/21/21/18 19/20/20/21
SCS 4/4/5/5 3/3/3/3 1/1/2/2
CYA 5/2/2/1 2/0/0/1 3/2/2/0
MTX 0/1/1/2 0/0/0/0 0/1/1/2
MMF 1/1/0/0 0/0/0/0 1/1/0/0
COM 2/0/0/0 0/0/0/0 2/0/0/0
COM, Combination therapy; CYA, cyclosporine; MMF, mycophenolate mofetil; MTX,
methotrexate; SCS, systemic corticosteroids; TCI, topical calcineurin inhibitors; TCS,
topical corticosteroids.
J ALLERGY CLIN IMMUNOL
VOLUME 137, NUMBER 6
LETTERS TO THE EDITOR 1884.e6
